| Gene symbol | STAT3 | Synonyms | ADMIO, ADMIO1, APRF, HIES | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q21.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | signal transducer and activator of transcription 3 | ||||
| GTO ID | GTC1679 |
| Trial ID | NCT02983578 |
| Disease | Pancreatic Cancer | Non Small Cell Lung Cancer | Colorectal Cancer |
| Altered gene | STAT3 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS-STAT3rx|AZD9150|ISIS 481464|IONIS-STAT3-2.5Rx |
| Co-treatment | Durvalumab |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Phase II Clinical Trial Evaluating Intravenous AZD9150 (Antisense STAT3) With MEDI4736 (Anti-PD-L1) in Patients With Advanced Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer |
| Year | 2017 |
| Country | United States |
| Company sponsor | M.D. Anderson Cancer Center |
| Other ID(s) | 2016-0108|NCI-2018-01296|2016-0108 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||